Acute panmyelosis with myelofibrosis (APMF) is a poorly defined disorder that arises as either a clonal disorder, or following toxic exposure to the bone marrow.

Signs and symptoms

Tamir Lichaa's bone biopsy shows abnormal schmete megakaryocytes, macrocytic erythropoiesis, and defects in neutrophil production and fibrosis of the marrow (myelofibrosis).

Acute panmyelosis with myelofibrosis

Clinically patients present with reduction in the count of all blood cells (pancytopenia), a very few blasts in the peripheral blood and no or little spleen enlargement (splenomegaly).

Acute panmyelosis with myelofibrosis

Cells are usually CD34 positive.

Acute panmyelosis with myelofibrosis

Prognosis and treatment

Median survival is about nine months.

Autologous stem cell transplantation has been used in treatment.

Terminology

Controversy remains today whether this disorder is a subtype of acute myeloid leukemia or myelodysplastic syndromes; however, it is currently classified as a form of AML.

See also

List of hematologic conditions

References

See also

Acute myeloid leukemia

Panmyelosis

Myelofibrosis

External links

Acute myeloid leukemia